title: Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan.
abstract: BACKGROUND
  The REduction of Atherothrombosis for Continued Health (REACH) Registry is an international observational study of patients with, or at risk of, atherothrombotic disease. Japanese patients were analyzed to clarify national prevalence and treatment.
  
  
  RESULTS
  Almost 68,000 outpatients were recruited worldwide with 5,193 in Japan. Among the Japanese patients, 83.7% had established vascular disease (symptomatic) and 16.3% had risk factors only (asymptomatic). Of the symptomatic patients, 14.0% had atherothrombotic lesions in more than 1 vascular bed, with 0.8% having lesions in 3 areas: brain, heart, and peripheral arteries. The prevalence of additional atherothrombotic risk factors among symptomatic patients was independent of the vascular lesion. Obesity was recorded in 10.6% and 42.1% of patients according to the National Cholesterol Education Program and Japanese guidelines, respectively. Pharmacologic intervention for risk factors was inadequate: only 37.7% of diabetic patients received antidiabetic medication, 79.6% of hypertensive patients used antihypertensives, and 74.0% received antiplatelet agents. The use of statins (44.1%) and aspirin (54.7%) was less common than seen in REACH globally.
  
  
  CONCLUSIONS
  Japanese patients enrolled in REACH share many similarities with the global population, but with some important differences. Long-term follow-up will determine the impact of these factors on the development of atherothrombotic events.
authors.affiliation: Department of Clinical Epidemiology and Systems, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. yama-tky@umin.ac.jp
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Shinya
authors.initials: S
authors.lastname: Goto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shigematsu
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shimada
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Uchiyama
authors.forename: Ryozo
authors.initials: R
authors.lastname: Nagai
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yamada
authors.forename: Masayasu
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Hideki
authors.initials: H
authors.lastname: Origasa
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
authors.forename: P Gabriel
authors.initials: PG
authors.lastname: Steg
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010353:Patient Education as Topic; D015995:Prevalence; D012042:Registries; D012307:Risk Factors; D013927:Thrombosis / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents